Diagnostic Reimbursement Strategy: What Founders Get Wrong

Most diagnostic founders treat reimbursement as a downstream activity — something to figure out after FDA clearance, after the product is built, after the first customers are signed.

This is one of the most common and most costly mistakes in diagnostic commercialization.

Reimbursement is not a billing function. It is a market access architecture decision that must be designed before launch.

The Coding Problem

Many diagnostic companies launch without a clear CPT code strategy. They assume existing codes will apply, or that a miscellaneous code will suffice.

In practice, miscellaneous codes create friction at every point in the reimbursement chain — from lab billing systems to payer adjudication. Without a specific code, providers face uncertainty, and uncertainty kills utilization.

Coverage Without Evidence

Payers do not cover tests because they are FDA-cleared. They cover tests that demonstrate clinical utility — evidence that the test changes clinical decisions and improves outcomes.

Most clinical studies are designed to satisfy regulators, not payers. The evidence required for coverage is fundamentally different from the evidence required for clearance.

• Regulators ask: Is the test accurate?
• Payers ask: Does the test change what a physician does?
• Health systems ask: Does it reduce cost or improve throughput?

The Payment Gap

Even with coding and coverage, payment rates may not support the company's commercial model. A test that costs $200 to deliver but reimburses at $50 is not commercially viable regardless of clinical performance.

Payment strategy must be modeled alongside product development, not discovered after launch.

A complete reimbursement strategy addresses three interlocking elements:

• Coding: Specific CPT or PLA code pathway, including timeline for application and approval
• Coverage: Clinical utility evidence aligned to payer decision-making frameworks
• Payment: Rate modeling that supports commercial viability across care settings

These elements must be designed in parallel with product development, not sequentially after clearance.

The window between FDA clearance and market entry is narrow. Companies that enter this window without a reimbursement strategy face months or years of commercial friction.

During that time, competitors advance, clinical champions lose interest, and investor patience erodes.

The companies that succeed design their reimbursement pathway 12–18 months before launch. They align clinical studies with payer requirements. They engage with coding bodies early. They model payment economics before finalizing their commercial model.

If your reimbursement strategy begins after clearance, you are already behind.

The most common failure pattern is not a bad test — it is a good test with no clear path to payment.

Reimbursement must be treated as a design constraint, not an administrative outcome.